Today I will be going through some of the preliminary data from the ReTune Study
📍Twin Cycle Hypothesis (R. Tayor 2008) of #type2diabetes
📍Once an individual' subcutaneous fat reserves are full
▶️ Fat is stored in the liver
▶️ Liver derived VLDL in turn, among other things, ⤴️ pancreatic fat
▶️⤴️pancreatic fat leads onto ⤵️ insulin secretion to food
What is the ReTUNE Study?
📍Similar to DiRECT except in non-obese (BMI<27) people with #type2diabetes
📍DM duration < 7 years
📍Similar intervention as DiRECT (i.e. at least 2 weeks of 800 Kcal/day meal replacement)
📍funded by @DUK_research 🙏
⚠️ Preliminary results only
📍 Full results due 2022
📍Intervention led to:
⤵️ liver fat
⤵️ pancreatic fat content
⤵️ wt.loss of 10-15kg assoc with similar levels of remission seen in DiRECT
👏👏👏
What does this mean?
📍 Wt. ⤵️ of 10-15kg early in #type2diabetes REGARDLESS of BMI can lead to remission‼️
📍 Extends the hope of remission to people with lower BMI
📍120mls whey protein microgels shot 😋 15 min before a meal
📍Results
⤵️ Post-prandial glucose by 22% (2h), 18% (3h)
⤵️ GLP-1 by 66%
⤵️ Insulin first phase by 61%
⚠️larger/longer studies planned
😒 not vegan friendly
Keep checking back to the @cardiomet_CE account as we have only just scratched the surface of the #EASD2021
Later today we will be asking the Qusetion "what next after metformin?" in the drug management of #type2diabetes reflections from Grade to TriMaster.
Hope everyone is enjoying the @GoggleDocs takeover of our feed. While we "rest" tied up in the @cardiomet_CE basement and others provide superb tweetorials on our behalf, let us remind you that . . .
This program is intended for healthcare professionals and is supported by educational grants from AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company, Chiesi, and NovoNordisk. And that you can see archived programs at cardiometabolic-ce.com
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Welcome to our final Goggledocs tweetorial from this #EASD2021 takeover!
Over the last few days we have discussed all things cardio-reno-metabolic including SGLT2s, GLP1s, dual agonists, triple agonists….but not mentioned much about type 1 diabetes…
So today we are going to end on a cardiometabolic focused look at Type 1 Diabetes with data from #EASD2021 interwoven in... stay tuned!
This accredited educational program is intended for healthcare providers only, and is supported by grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk. Follow this thread for a link to credit. CE/#CME credit for #physicians, #nurses, #pharmacists in US, Canada, GB, EU.
STEP this way for the last of our tweetorials covering #ESCCongress@escardio Looking at a trial of intensive blood pressure control in older adults with hypertension
First...step aside to a different STEP trial – Semaglutide in Obesity – our last tweetorial on this was very popular – have a look!